MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BX471

CAS No. : 217645-70-0

MCE 站：BX471

产品活性：BX471 (ZK-811752) 是以一种口服有效的，选择性，非多肽的 CCR1 拮抗剂，K_i 值为 1 nM，对其选择性是对 CCR2，CCR5 和 CXCR4 的 250 倍。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CCR

In Vitro: BX471 is a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca²⁺ mobilization, increase in extracellular acidification rate, CD11b expression, ａnd leukocyte migration. BX471 demonstrats a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. BX471 is also able to displace ¹²⁵I-MIP-1α/CCL3 binding to mouse CCR1 in a concentration-dependent manner with a K_i of 215±46 nM. Increasing concentrations of BX471 inhibits the Ca²⁺ transients induced by MIP-1α/CCL3 in both human ａnd mouse CCR1 with IC₅₀ of 5.8±1 nM ａnd 198±7 nM, respectively. BX471 (0.1-10 μM) shows a dose-dependent inhibition of RANTES-mediated ａnd shear-resistant adhesion on IL-1β-activated microvascular endothelium in shear flow in isolated blood monocytes. BX471 also inhibits the RANTES-mediated adhesion of T lymphocytes to activated endothelium.

In Vivo: BX471 (4 mg/kg, p.o. or i.v.) is orally active with a bioavailability of 60% in dogs. Furthermore, BX471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. BX471 (20 mg/kg, s.c.) reaches peak plasma levels of 9 μM by around 30 minutes, ａnd this rapidly declines to approximately 0.4 μM after 2 hours. From 4 to 8 hours the drug plasma levels drops to 0.1 μM or lower. Mice treated with 20 mg/kg of BX471 for 10 days shows a reduction of interstitial CD45 positive leukocytes of approximately 55%. BX471 has a borderline significant effect on the number of CCR5-positive CD8 cells in the peripheral blood. BX471 reduces the amount of FSP1-positive cells by 65% in UUO kidneys as compared with vehicle control. Pretreatment witih BX471 reduces macrophage ａnd neutrophil accumulation in kidney after ischemia-reperfusion injury.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Endocrinology Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Pirfenidone  |  Maraviroc  |  RS 504393  |  INCB3344  |  PF-4136309  |  Bindarit  |  Cenicriviroc  |  TAK-779  |  RS102895 hydrochloride  |  AZ084  |  CCR6 inhibitor 1  |  BMS-813160  |  BX471 hydrochloride  |  Vercirnon  |  AZD2098  |  CCR2-RA-[R]  |  MK-0812 Succinate  |  INCB 3284  |  7,4＇-Dihydroxyflavone  |  CCR7 Ligand 1  |  CCR2 antagonist 4 hydrochloride  |  GW 766994  |  J-113863  |  K777  |  TAK-220  |  Vicriviroc maleate  |  DAPTA  |  ML604086  |  LMD-009

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。